1. Home
  2. SKYE
  3. SKYE News

Latest Skye Bioscience Inc. Common Stock (SKYE) News on February 5, 2025

Skye Bioscience Announces Participation in February Conferences
SKYE

GlobeNewswire

a day ago

Skye Bioscience Announces Participation in February Conferences

Skye Bioscience Provides 2025 Look Ahead and Year in Review
SKYE

GlobeNewswire

23 days ago

Skye Bioscience Provides 2025 Look Ahead and Year in Review

Skye Bioscience to Present at J.P. Morgan Healthcare Conference
SKYE

GlobeNewswire

2 months ago

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
SKYE

GlobeNewswire

3 months ago

Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences

Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond
SKYE

TipRanks

3 months ago

Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
SKYE

GlobeNewswire

3 months ago

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
SKYE

GlobeNewswire

3 months ago

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model
SKYE

GlobeNewswire

3 months ago

Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

Skye Bioscience to Announce Third Quarter 2024 Results
SKYE

GlobeNewswire

3 months ago

Skye Bioscience to Announce Third Quarter 2024 Results

Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
SKYE

GlobeNewswire

3 months ago

Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
SKYE

GlobeNewswire

3 months ago

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
SKYE

GlobeNewswire

4 months ago

Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan

Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer
SKYE

GlobeNewswire

5 months ago

Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
SKYE

GlobeNewswire

5 months ago

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SKYE

GlobeNewswire

5 months ago

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
SKYE

GlobeNewswire

5 months ago

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
SKYE

GlobeNewswire

6 months ago

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity
SKYE

GlobeNewswire

6 months ago

Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity

Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
SKYE

GlobeNewswire

6 months ago

Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
SKYE

GlobeNewswire

7 months ago

Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab
SKYE

GlobeNewswire

7 months ago

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
SKYE

GlobeNewswire

7 months ago

Skye Bioscience Appoints Dr. Karen Smith to Board of Directors

Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes
SKYE

GlobeNewswire

7 months ago

Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes

Skye BioScience Participating in Piper Sandler Virtual Obesity Day
SKYE

GlobeNewswire

7 months ago

Skye BioScience Participating in Piper Sandler Virtual Obesity Day

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities
SKYE

PR Newswire

8 months ago

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*
SKYE

GlobeNewswire

8 months ago

Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*

SKYE

Business Wire

8 months ago

Form 8.3 - Darktrace plc

SKYE

Business Wire

8 months ago

Form 8.3 - International Distribution Services plc

US Supreme Court rejects Kroger challenge to Grubhub trademark win
SKYE

Reuters

8 months ago

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect
SKYE

Investor's Business Daily

8 months ago

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

SKYE

GlobeNewswire

8 months ago

Middlefield Canadian Income PCC: Net Asset Value(s)

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina
SKYE

Business Wire

8 months ago

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program
SKYE

GlobeNewswire

8 months ago

Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

Skye Bioscience to Present at Jefferies Global Healthcare Conference
SKYE

GlobeNewswire

8 months ago

Skye Bioscience to Present at Jefferies Global Healthcare Conference

Skye Bioscience, Inc.'s (NASDAQ:SKYE) last week's 13% decline must have disappointed private equity firms who have a significant stake
SKYE

Simply Wall St.

9 months ago

Skye Bioscience, Inc.'s (NASDAQ:SKYE) last week's 13% decline must have disappointed private equity firms who have a significant stake

Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
SKYE

GlobeNewswire

9 months ago

Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting

Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
SKYE

GlobeNewswire

9 months ago

Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting

Skye Bioscience to Present at Upcoming Investment Conferences
SKYE

GlobeNewswire

9 months ago

Skye Bioscience to Present at Upcoming Investment Conferences

Share on Social Networks: